Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00208299 · ClinicalTrials.gov registry record · Phase 3
ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,231
- Enrollment target
NCT00208299: Completed Phase 3 study, sponsored by Gilead Sciences.
NCT00208299 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 1,231 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (59% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00208299, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,231 participants
- Enrollment target
Study Summary
Adenoscan® (adenosine) is an approved pharmacological stress agent indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. The investigational drug, regadenoson (CVT-3146) is a selective A2A adenosine receptor agonist, the receptor responsible for coronary vasodilation, and is being studied for potential use as a pharmacologic stress agent in myocardial perfusion imaging (MPI) studies. This study will compare the safety and efficacy of regadenoson to that of Adenoscan in detecting reversible myocardial perfusion defects.
Interventions
- DRUG Regadenoson
- DRUG Adenosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,231 participants |
| Start Date | 2003-10 |
| Est. Completion | 2006-08 |
| Phase | Phase 3 |
What the finished NCT00208299 record still lists
NCT00208299 is an interventional study that assigns participants to a tested intervention. Its 1,231 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (59% higher).
The record links to 0 conditions, and to 2 interventions - of which Regadenoson is the first listed.
NCT00208299 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00208299 about?
NCT00208299 is a clinical study titled "ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)". Adenoscan® (adenosine) is an approved pharmacological stress agent indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. The investigational drug, regadenoson (CVT-3146) is a selective A2A adenosine receptor agonist, the receptor respons...
What is the current status of trial NCT00208299?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,231 participants. The study started on 2003-10. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00208299?
The interventions under investigation include: Regadenoson (DRUG), Adenosine (DRUG).
Who is sponsoring clinical trial NCT00208299?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00208299's enrollment target sits among peer trials
1,231 214th of 2000 higher than 1,787 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05456841 · 1,232 participants · NA
Empathic Communication Skills (ECS) Training
- NCT05946044 · 1,230 participants · NA
The Osteoarthritis Prevention Study
- NCT06787937 · 1,230 participants · NA
Communicating About Nicotine Reduction in Cigarettes
- NCT06921785 · 1,220 participants · Phase 3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia